20/05/2025
Today, on International Clinical Trials Day, we at Ameli-BioGroup salute the dedication, innovation and collaboration that power clinical research. 🌍🔬
Since James Lind’s pioneering scurvy study in 1747—the very first randomised trial—every protocol, every volunteer and every data point has brought us closer to safer, more effective treatments.
Interesting facts 📊
• 🧪 Origin story: 20 May marks Lind’s 1747 trial aboard HMS Salisbury, in which he proved that citrus fruit prevents scurvy—laying the groundwork for modern, evidence‑based medicine.
• 🚀 High bar: despite thousands of trials underway worldwide, only 10 % of drug candidates entering human testing ultimately gain approval.
• ⏳ Recruitment hurdles: 80 % of trials miss their patient‑recruitment deadlines, costing the industry up to $40 billion annually in delays.
• 🌐 Decentralised future: the global decentralised clinical‑trials market was worth $9.6 billion in 2024 and is projected to more than double to $21.3 billion by 2030, as patient‑centred models reshape how studies are run.
At Ameli-BioGroup, we’re proud to support Phase II–IV trials across therapeutic areas, leveraging cutting‑edge technology and patient‑centred approaches to accelerate breakthroughs.
Today we reaffirm our pledge to:
• Uphold the highest ethical and quality standards
• Foster transparent communication with all stakeholders
• Champion diversity and inclusion in every study design
Join us in celebrating the power of clinical trials to change lives! 💙
🔗 Learn more about our ongoing studies: https://lnkd.in/ew9cSFjw
-Biogroup LTD